Comparative Genomics and Pathogenicity of Agents of Human and Animal Fungal Infections

Clinical Center

Investigators

Linked publications & trials

Abstract

Fungal infections are increasingly recognized as a major global health threat, placing a significant burden on human populations across diverse regions. Every year, it is estimated that over one billion people worldwide are affected by fungal infections and fungal-related allergies. These conditions range from superficial infections that, while not immediately life-threatening, can cause chronic discomfort and reduced quality of life, to severe systemic infections that are associated with high mortality. Alarmingly, fungal diseases are responsible for more than 3 million deaths annually, a toll that rivals or exceeds that of many better-recognized infectious diseases. Despite this impact, fungal infections often remain underappreciated in the broader public health agenda, partly because of diagnostic limitations and insufficient investment in antifungal drug development. Individuals at greatest risk for life-threatening fungal infections typically fall into vulnerable patient populations. These include people with weakened immune systems, whether due to primary immunodeficiencies of genetic origin or acquired immunodeficiencies such as those caused by HIV/AIDS. In addition, patients undergoing treatment for cancer, individuals suffering from major trauma, and those who have received solid organ or hematopoietic stem cell transplants face particularly high risks. Immunosuppressive therapies, especially corticosteroid treatment, further compound susceptibility by impairing host defenses. As a result, invasive fungal diseases are commonly observed in hospital and intensive care settings, where patients are already struggling with multiple underlying health challenges. Over the last decade, significant changes have occurred in the epidemiology of invasive fungal infections. While long-recognized pathogens such as Candida albicans and Aspergillus fumigatus remain prominent, there has been a troubling increase in the emergence of novel fungal pathogens. These include rare species that were previously considered non-pathogenic but are now capable of causing disease in both immunocompromised and, increasingly, immunocompetent patients. This shift underscores the adaptability of fungi as opportunistic organisms and highlights the pressing need for updated surveillance, improved diagnostics, and new therapeutic strategies to combat these evolving threats. The central objective of this study is to deepen our understanding of fungal pathogenesis by examining the molecular diversity, epidemiology, and infection biology of opportunistic fungal pathogens isolated from hospitalized patients. Our focus will be on patients with both primary and secondary immunodeficiencies, many of whom are enrolled in clinical trials at the NIH and other collaborating institutions. Because these patients come from diverse geographic backgrounds, the isolates we study will reflect a wide array of fungal species and strain variations, providing a unique opportunity to characterize global patterns of infection. To achieve these goals, we will employ a broad range of complementary research methodologies. Functional genomics and proteomics will be used to dissect the molecular mechanisms that enable fungal pathogens to adapt to and exploit weakened host defenses. Microbiological techniques will allow us to characterize growth dynamics, morphologic transitions, and virulence traits under laboratory conditions. Pre-clinical and translational research approaches will then be used to evaluate how these findings can be applied in a clinical context, ultimately informing patient care. Additionally, we will compare clinical isolates with fungal species of animal origin that display similar thermotolerance, dimorphism, and virulence behavior. This comparative approach will help us uncover evolutionary and ecological factors that contribute to pathogenic potential. Finally, we will assess the susceptibility of these clinical isolates to currently available antifungal agents. By mapping resistance patterns and identifying trends, our work aims to provide actionable data that can guide treatment decisions and inform the development of new antifungal therapies. Ultimately, this study seeks to bridge fundamental molecular insights with clinical relevance, advancing our knowledge of opportunistic fungi while addressing an urgent and growing threat to human health.